<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03905252</url>
  </required_header>
  <id_info>
    <org_study_id>IRB # 09-003156</org_study_id>
    <nct_id>NCT03905252</nct_id>
  </id_info>
  <brief_title>Biomarkers for Human Heart Failure</brief_title>
  <acronym>Biomarkers</acronym>
  <official_title>Biomarkers for Human Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the various ranges of proteins that can be assayed
      in the plasma and urine from hospitalized patients with all classes of heart failure and/or
      STEMI (ST-segment elevation myocardial infarction)/NSTEMI (Non-ST-segment elevation
      myocardial infarction), as well as history reviews.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schematic Design of the Study: Single blood draw, one random urine and 24-hr urine collection
      from hospitalized patients with chronic/acute heart failure and/or STEMI-NSTEMI. If there
      should be a subsequent hospitalization,another collection of a 45 ml blood sample, random
      urine and one 24-hour urine collection may be completed if indicated at initial
      hospitalization.

      Aims:

      The purpose of this study is to attempt to establish the various ranges of proteins that can
      be assayed from the plasma and urine of patients with all classes of heart failure and MI
      (myocardial infarction). Follow-up hospitalizations may result in another 45 ml blood draw,
      random urine and 24-hr. urine collection to evaluate the outcome of the heart failure
      treatment used with the previous hospitalization, if indicated in consent. A history review
      will be necessary as well.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>uAGT levels in high-risk chronic HF patients</measure>
    <time_frame>10 years</time_frame>
    <description>This study will provide new knowledge of the pathology and outcomes predicted by the use of uAGT in symptomatic chronic HF patients at high risk for future hospitalization and death.</description>
  </primary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>CHF</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sample analysis</intervention_name>
    <description>blood, Random urine sample and 24-hour urine samples</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      : Single blood draw, random urine and 24-hr urine collection
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Eight Hundred HF patients hospitalized for symptomatic HF at Mayo Clinic Hospital - St
        Mary's Campus, Rochester, Minnesota
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Diagnosis of Acute decompensated heart failure

        Exclusion Criteria:

        • Hemoglobin less than 10, active cancer, or amyloidosis Patient with dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>John C Burnett, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seethalakshmi R Iyer, MS</last_name>
    <phone>507-284-4838</phone>
    <email>iyer.seethalakshmi@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emery (John) van Hook</last_name>
    <phone>507-284-4838</phone>
    <email>VanHook.Emery@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Foundation</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seethalakshmi Iyer, MS</last_name>
      <phone>507-284-4838</phone>
      <email>iyer.seethalakshmi@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emery (John) Van Hook</last_name>
      <phone>507-284-4838</phone>
      <email>VanHook.Emery@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John C Burnett, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 4, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>John C Burnett</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

